Skip to main content

Advertisement

Table 1 Clinicopathological features of 114 patients and chemo-effects

From: Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

  pCR   non-pCR   p value
n 11   103   
Mean age (SD) 54.6 (16.4) 50.9 (11.1) n.s.
Mean tumour sizea (mm) (SD) 35.9 (18.1) 36.0 (15.7) n.s.
Histology      
Ductal 11   98   n.s.
Lobular 0   5   
High nuclear grade 27% (3/11) 22% (22/99) n.s.
ERb 100% (114/114) 100% (114/114) n.s.
PRb 45% (5/11) 78% (80/103) <0.05
Mean Ki67 (%) (SD)c 43.0 (30.0) 33.6 (18.1) <0.01
  1. ER: estrogen receptor, PR: progesterone receptor, n.s.: not significant.
  2. aclinical size measured by ultrasound before treatments.
  3. brates of positive (more than 10% of the nuclei of cancer cells) cases.
  4. cdot chart shown in Additional file 1: Figure S1.
  5. The NAC response was significantly better in patients with tumours highly expressing Ki67 (p < 0.01). PR-negative tumours also showed better responses to chemotherapy (p < 0.05).